CORE

🇺🇦   make metadata, not war

    1 research outputs found

    Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome

    Author
    Publication venue
    'American Society of Hematology'
    Publication date
    Field of study
    Full text link
    Crossref
    corecore